CiQUS researchers develop a broad-spectrum inhibitor to combat infections caused by P. aeruginosa, the paradigm of bacterial resistance to antibiotics.
The compounds developed by Prof. González Bell...
The work of the Epidemiology of Bacterial Infections research group of IDIBELL and HUB indicates that the bacteria could achieve the resistance through the acquisition of mobile DNA fragments.
An alternative to the use of antibiotics created by the group of Dr. Rafael Mañez, from the Bellvitge Biomedical Research Institute (IDIBELL) and the Bellvitge University Hospital (HUB), has been sel...
A study coordinated by researchers of the Clínic-IDIBAPS and published in The Lancet Gastroenterology & Hepatology establishes the safe dose of simvastatin to be used together with rifaximin, an a...
Patients with solid organ transplants, due to the transplant process itself, hospital admission and immunosuppression, among other factors, are frequently colonized or infected by antibiotic resistant...